ING Knock-Out RO/ DE000NG9CJY4 /
9/6/2024 4:40:22 PM | Chg.-0.100 | Bid5:19:50 PM | Ask5:19:50 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.860EUR | -3.38% | - Bid Size: - |
- Ask Size: - |
ROCHE I | 270.827 CHF | 12/31/2078 | Call |
GlobeNewswire
8/26
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborat...
GlobeNewswire
8/8
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
GlobeNewswire
8/8
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Updat...
GlobeNewswire
6/18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
6/14
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...
GlobeNewswire
6/11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
5/9
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
4/3
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire
4/2
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
3/22
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...
GlobeNewswire
3/14
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire
2/26
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire
2/21
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Rep...